文献速递泌尿生殖与妇科肿瘤放疗

低剂量率近距离放射治疗前列腺癌患者的临床与生化结局的种族分析

Racial Analysis of Clinical and Biochemical Outcomes in Patients With Prostate Cancer Treated With Low-Dose-Rate Brachytherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-11-03

该回顾性研究纳入2005至2018年接受确定性低剂量率近距离放射治疗的167例前列腺癌患者(黑人81例,占48.5%),中位随访88.4个月。黑人患者社会经济状况更差,但5年无生化失败生存率总体为92.3%(95%CI 87.8%-96.8%),7年为87.7%(95%CI 82.0%-93.4%),黑人与非黑人患者间无显著差异(P=.114)。黑人种族并非失败的独立预测因素(HR 1.51,95%CI 0.56-4.01,P=.42)。

要点

  • 黑人患者更多来自低收入社区且社会脆弱性更高(P<.01)。
  • 黑人与非黑人患者的无生化失败生存率无显著差异(P=.114)。
  • 仅最低前列腺特异性抗原与生化失败显著相关(HR 3.57,95%CI 2.44-5.22,P<.001)。

核心结论

  • 接受低剂量率近距离放射治疗的黑人前列腺癌患者尽管社会经济状况较差,其无生化失败生存率与非黑人患者相似。
  • 作者认为,近距离放射治疗可能消除部分临床结局差异。

研究设计与样本

  • 回顾性机构审查委员会批准方案,收集2005年至2018年所有接受确定性低剂量率近距离放射治疗的患者数据。
  • 共纳入167例患者,其中黑人81例(48.5%),中位随访88.4个月。
  • 采用Pearson χ2分析比较两组人口学和肿瘤差异,Kaplan-Meier法计算无生化失败生存率,单因素和多因素分析识别生化失败预测因素。

主要发现

  • 黑人患者来自较低收入社区(P<.01),社会脆弱性更高(P<.01),诊断至治疗间隔更长(P=.011)。
  • 总体累积无生化失败生存率5年为92.3%(95%CI 87.8%-96.8%),7年为87.7%(95%CI 82.0%-93.4%)。
  • 黑人与非黑人患者无生化失败生存率无显著差异(P=.114)。
  • 黑人种族并非失败的独立预测因素(HR 1.51,95%CI 0.56-4.01,P=.42)。
  • 两组总生存期相当(P=.972);多因素分析中仅最低前列腺特异性抗原与生化失败显著相关(HR 3.57,95%CI 2.44-5.22,P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Black men in the United States experience significantly higher incidence of and mortality from prostate cancer (PCa) than non-Black men. The cause of this disparity is multifactorial, though inequitable access to curative radiation modalities, including low-dose-rate (LDR) brachytherapy, may contribute. Despite this, there are few analyses evaluating the potential of different radiation therapies to mitigate outcome disparities. Therefore, we examined the clinical outcomes of Black and non-Black patients treated with definitive LDR brachytherapy for PCa. METHODS: Data were collected for all patients treated with definitive LDR brachytherapy between 2005 and 2018 on a retrospective institutional review board approved protocol. Pearson χ2 analysis was used to assess demographic and cancer differences between Black and non-Black cohorts. Freedom from biochemical failure (FFBF) was calculated using Kaplan-Meier analysis. Univariate and multivariate analyses were used to identify factors predictive of biochemical failure. RESULTS: One hundred and sixty-seven patients were included in the analysis (Black: n = 81; 48.5%) with a median follow-up of 88.4 months. Black patients were from lower income communities (P < .01), had greater social vulnerability (P < .01), and had a longer interval between diagnosis and treatment (P = .011). Overall cumulative FFBF was 92.3% (95% confidence interval [CI], 87.8%-96.8%) at 5 years and 87.7% (95% CI, 82.0%-93.4%) at 7 years. There was no significant difference in FFBF in Black and non-Black patients (P = .114) and Black race was not independently predictive of failure (hazard ratio, 1.51; 95% CI, 0.56-4.01; P = .42). Overall survival was comparable between racial groups (P = .972). Only nadir prostate-specific antigen was significantly associated with biochemical failure on multivariate (hazard ratio, 3.57; 95% CI, 02.44-5.22; P < .001). CONCLUSIONS: Black men treated with LDR brachytherapy achieved similar FFBF to their non-Black counterparts despite poorer socioeconomic status. This suggests that PCa treatment with brachytherapy may eliminate some disparities in clinical outcomes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kerans SJ, Samanta S, Vyfhuis MAL, et al. Racial Analysis of Clinical and Biochemical Outcomes in Patients With Prostate Cancer Treated With Low-Dose-Rate Brachytherapy. Int J Radiat Oncol Biol Phys. 2022. PMID: 36336224. doi:10.1016/j.ijrobp.2022.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。